Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis
Sayeepriyadarshini Anakk, Mitsuhiro Watanabe, Scott A. Ochsner, Neil J. McKenna, Milton J. Finegold, David D. Moore
Sayeepriyadarshini Anakk, Mitsuhiro Watanabe, Scott A. Ochsner, Neil J. McKenna, Milton J. Finegold, David D. Moore
View: Text | PDF
Research Article Hepatology

Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis

  • Text
  • PDF
Abstract

Bile acid homeostasis is tightly regulated via a feedback loop operated by the nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner (SHP). Contrary to current models, which place FXR upstream of SHP in a linear regulatory pathway, here we show that the phenotypic consequences in mice of the combined loss of both receptors are much more severe than the relatively modest impact of the loss of either Fxr or Shp alone. Fxr–/–Shp–/– mice exhibited cholestasis and liver injury as early as 3 weeks of age, and this was linked to the dysregulation of bile acid homeostatic genes, particularly cytochrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1). In addition, double-knockout mice showed misregulation of genes in the C21 steroid biosynthesis pathway, with strong induction of cytochrome P450, family 17, subfamily a, polypeptide 1 (Cyp17a1), resulting in elevated serum levels of its enzymatic product 17-hydroxyprogesterone (17-OHP). Treatment of WT mice with 17-OHP was sufficient to induce liver injury that reproduced many of the histopathological features observed in the double-knockout mice. Therefore, our data indicate a pathologic role for increased production of 17-hydroxy steroid metabolites in liver injury and suggest that Fxr–/–Shp–/– mice could provide a model for juvenile onset cholestasis.

Authors

Sayeepriyadarshini Anakk, Mitsuhiro Watanabe, Scott A. Ochsner, Neil J. McKenna, Milton J. Finegold, David D. Moore

×

Figure 1

Increased liver and gallbladder size indicates hepatobiliary dysfunction in FXR/SHP DKO mice.

Options: View larger image (or click on image) Download as PowerPoint
Increased liver and gallbladder size indicates hepatobiliary dysfunction...
(A) Genotyping PCR confirms the generation of DKO mice. (B) DKO mice exhibit hepatomegaly. Increased (C) gallbladder and (D) liver size occurs only in 10- to 12-week-old DKO mice. (E) Increased hepatocyte Ki-67 staining, marked by arrows, indicates increased cellular proliferation in the 10-week-old DKO liver. Brown-stained nuclei show Ki-67–positive cells, and its quantification is shown in F. Original magnification, ×125 (E). Data are presented as mean ± SEM, n = 8–15. **P < 0.001 when compared with WT.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts